PROSTOX is Clinically Validated to Help Physicians Identify Patients at Risk of Developing Significant Late-Onset Genitourinary (GU) Toxicity

Patients at high risk have a ~75% chance of developing toxicity from SBRT or CFRT. This valuable insight enables the risk of toxicity to be part of the cancer treatment consideration.

Discover Precision, Clarity, and Confidence

Combined analysis of clinical validation and research studies accessing PROSTOX ultra performance.

94%

SPECIFICITY*

76%

PPV*

Positive Predictive Value

86%

NPV*

Negative Predictive Value

10Fold

LESS TOXICITY**

Late grade ≥ 2 GU

*Kishan et al. Clin Cancer Res 2025.
**Kishan et al. Radiother Oncol 2022.

Publications

MiraDx is paving the future of personalized medicine, enabling safer, more effective treatment decisions tailored to each patient’s unique genetic profile.

Explore our publications and learn how PROSTOX can transform your patients’ cancer care.

2025 | Clinical Validation

PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial

Phase III, randomized clinical study

PROSTOX can accurately predict late Grade ≥ 2 GU toxicity after SBRT, regardless of treatment modality.

See Publication

2023 | Clinical Utility

The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making

Phase II, single-center, prospective clinical study

PROSTOX predicts toxicity risk from SBRT or CFRT and influences treatment decisions for localized prostate cancer.

See Publication

2023 | POST-OP Clinical Validation

Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial

Phase II, dual-center, single-arm clinical study

PROSTOX identifies a higher risk for late grade ≥ 2 genitourinary (GU) toxicity following post-prostatectomy SBRT.

See Publication

2022 | Development Study

Germline variants disrupting microRNAs predict long-term GU toxicity after prostate cancer radiation

Developmental Study

Germline mirSNP-based predictive models effectively forecast late-grade ≥ 2 GU toxicity following CFRT or SBRT.

See Publication

PROSTOX

Overview

How to order